1-苄基-4-苯基哌啶-4-甲酰胺 | 84176-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-苯基哌啶-4-甲酰胺
• 英文名称: 1-benzyl-4-phenyl-piperidine-4-carboxylic acid amide
• 英文别名: 1-Benzyl-4-phenyl-piperidin-4-carbonsaeure-amid；1-benzyl-4-phenylpiperidine-4-carboxamide；1-benzyl-4-phenyl-4-piperidinecarboxamide
• CAS: 84176-76-1
• 化学式: C₁₉H₂₂N₂O
• mdl: MFCD18430304
• 分子量: 294.396
• InChiKey: LTUVVZKXVNALKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.315
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-苄基-4-苯基哌啶-4-甲酰胺 在 palladium on carbon 、 氢气 作用下， 以 乙醇 为溶剂， 以95%的产率得到4-carbamoyl-4-phenylpiperidine
  参考文献：
  名称：

  Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities

  摘要：

  A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.08.047
• 作为产物：
  描述：

  1-苄基-4-苯基哌啶-4-羧酸 在 氯化亚砜 作用下， 生成 1-苄基-4-苯基哌啶-4-甲酰胺
  参考文献：
  名称：

  447.合成止痛药和相关化合物。第一部分。和4：5-二氢乙二醛

  摘要：

  DOI：

  10.1039/jr9500002173

文献信息

• Method for preparing 4-methylamino-4-phenylpiperidine
  申请人：——

  公开号：US20040181071A1

  公开（公告）日：2004-09-16

  The invention relates to a process for preparing a 4-alkoxycarbonylamino-1-benzyl-4-phenylpiperidine of formula (I) 1 via hydrolysis of 1-benzyl-4-cyano-4-phenylpiperidine (II) in acidic medium and treatment of the 1-benzyl-4-phenyl-4-piperidinecarboxamide (III) thus obtained with bromine in the presence of an alkali metal alkoxide. The invention also relates to a process for preparing 4-methylamino-4-phenylpiperidine from compound (II).

  该发明涉及一种制备4-烷氧羰基氨基-1-苄基-4-苯基哌啶的方法，通过在酸性介质中水解1-苄基-4-氰基-4-苯基哌啶（II），并将得到的1-苄基-4-苯基-4-哌啶羧酰胺（III）与溴在碱金属碱中存在的条件下处理。该发明还涉及一种从化合物（II）制备4-甲氨基-4-苯基哌啶的方法。
• Heterocyclo inhibitors of potassium channel function
  申请人：Lloyd John

  公开号：US20060014792A1

  公开（公告）日：2006-01-19

  Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ), methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds.

  新型杂环化合物可用作钾通道功能的抑制剂（尤其是Kv1电压门控K+通道的抑制剂，特别是抑制Kv1.5，该通道已与超快速激活延迟整流K+电流IKur相关联），使用这种化合物预防和治疗心律失常和IKur相关病症的方法，以及含有这种化合物的制药组合物。
• HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION
  申请人：Lloyd John

  公开号：US20090312307A1

  公开（公告）日：2009-12-17

  Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ), methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds.

  新型杂环化合物，可作为钾通道功能抑制剂使用（特别是Kv1亚家族电压门控K+通道的抑制剂，特别是与超快速激活延迟整流K+电流IKur相关的Kv1.5抑制剂），使用这种化合物预防和治疗心律失常和IKur相关疾病的方法，以及含有这种化合物的制药组合物。
• Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists
  作者：Timothy P. Burkholder、Elizabeth M. Kudlacz、George D. Maynard、Xiao-Gao Liu、Tieu-Binh Le、Mark E. Webster、Stephen W. Horgan、David L. Wenstrup、David W. Freund、Fred Boyer、Larry Bratton、Raymond S. Gross、Robert W. Knippenberg、Deborah E. Logan、Bryan K. Jones、Teng-Man Chen、Julie L. Geary、Melinda A. Correll、J. Chuck Poole、Arun K. Mandagere、Thomas N. Thompson、Kin-Kai Hwang

  DOI：10.1016/s0960-894x(97)10013-0

  日期：1997.10

  We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors.(1) Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration. (C) 1997 Elsevier Science Ltd.
• NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT
  申请人：Astra Aktiebolag

  公开号：EP0743940B1

  公开（公告）日：2000-05-03